Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I

Afsar Ali Mian1, Anna Metodieva1, Susanne Badura1, Mamduh Khateb2, Nili Ruimi2, Yousef Najajreh3, Oliver Gerhard Ottmann1, Jamal Mahajna24 and Martin Ruthardt15*

Author affiliations

1 Department of Hematology, Goethe University, Frankfurt, Germany

2 Cancer Drug Discovery, Migal-Galilee Technology Center, Kiryat Shmona, Israel

3 Faculty of Pharmacy, Al-Quds University, Jerusalem-Abu Dies, Palestine

4 Departments of Nutritional Sciences, Tel Hai Academic College, Kiryat Shmona, Israel

5 Labor für Tumorstammzellbiologie, Med. Klinik II/Hämatologie, Klinikum der Goethe Universität Frankfurt, Theodor Stern Kai 7, 60590, Frankfurt, Germany

For all author emails, please log on.

Citation and License

BMC Cancer 2012, 12:411  doi:10.1186/1471-2407-12-411

Published: 17 September 2012



Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity. The constitutively activated BCR/ABL-kinase “escapes” the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR/ABL restores allosteric inhibition. Given the fact that all AKIs fail to inhibit BCR/ABL harboring the ‘gatekeeper’ mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.


The efficacy of this approach on the leukemogenic potential of BCR/ABL was studied in Ba/F3 cells, primary murine bone marrow cells, and untransformed Rat-1 fibroblasts expressing BCR/ABL or BCR/ABL-T315I as well as in patient-derived long-term cultures (PDLTC) from Ph + ALL-patients.


Here, we show that GNF-2 increased the effects of AKIs on unmutated BCR/ABL. Interestingly, the combination of Dasatinib and GNF-2 overcame resistance of BCR/ABL-T315I in all models used in a synergistic manner.


Our observations establish a new approach for the molecular targeting of BCR/ABL and its resistant mutants using a combination of AKIs and allosteric inhibitors.

Philadelphia chromosome; BCR/ABL; “gatekeeper” mutation T315I; Allosteric inhibition; Abl kinase inhibitors; Molecular therapy